top of page

South Africa's (SAPHRA): Guideline on Pharmacovigilance Systems

Writer's picture: Sharan MuruganSharan Murugan

Earlier today (06 June, 2023) the South African Health Products Regulatory Authority (SAPHRA) released an updated Guideline on "Pharmacovigilance Systems".


A pharmacovigilance system consists of specific pharmacovigilance processes that are purposed to ensure good pharmacovigilance practice.

A pharmacovigilance system is a system used by applicants/Holder of Certificate of Registration to fulfill their legal mandate and responsibilities in relation to pharmacovigilance and is designed to monitor the safety of all registered health products and detect any change to their risk-benefit balance.


This is to ensure that evidence of adverse events, interactions, and information regarding post-market surveillance and vigilance is monitored, analyzed and responded to in a functional pharmacovigilance system operated by the HCR.


The purpose of this guidance is to facilitate compliance by HCRs and to enhance consistency in the application of regulatory requirements governing good pharmacovigilance practices.


The guidelines provide an overview of all aspects of a quality-assured pharmacovigilance system, including risk management. They provide guidance as to what is expected of holders of certificates of registration in relation to pharmacovigilance systems.

  • Have an adequate and effective pharmacovigilance system and its quality system for monitoring the medicines that are registered in order to protect public health

  • maintain a pharmacovigilance system master file (PSMF)

  • have adequate, competent, appropriately qualified and trained staff to work on the pharmacovigilance system

  • comply with the pharmacovigilance obligations as per the Medicines and Related Substances Act

Click this LINK to know more about the qualifications of QPPV etc.

Comentarios


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page